

Curriculum Vitae

David Weill, M.D.

Current Position

Title: Principal, Weill Consulting Group

Work Address: 8616 Oak Street, Suite 101, New Orleans, LA 70118
Telephone (office): (504) 558-4942
E-Mail: david@weillconsulting.com

License No: C52127 (CA); ME 130463 (FL); 304283 (LA)

Place of Birth: New Orleans, LA

Citizenship: U.S.

Marital Status: Married

Undergraduate Education:

1985 Bachelor of Arts, Political Science, Tulane University, New Orleans, LA
Cum Laude

Graduate Education:

1990 M.D., Tulane University Medical School

Postdoctoral Training:

06/90-06/93 Internship and Residency in Internal Medicine, Parkland Hospital,
University of Texas - Southwestern

07/93-06/96 Fellowship in Pulmonary and Critical Care Medicine and Lung
Transplantation, University of Colorado at Denver and Health Sciences
Center (UCDHSC)

Honors and Awards:

2019 The Grace Rose Foundation, Medical Professional of the Year
2010 Cystic Fibrosis Research Institute, Professional of the Year

Licensure and Certification:

1993-2003 American Board of Internal Medicine, Internal Medicine
1996 Diplomate in Pulmonary Disease (recertified until 2026)
2006 Diplomate in Critical Care Medicine

Grants:**Present/Pending:**

- 2011-2014 National Institutes of Health, RC4, RFA-OD-10-005
Genome Transplant: A non-invasive sequencing-based method for detecting acute and chronic rejection of solid organ transplants
Co-investigator, 5% effort (Principal Investigators: Hannah Valentine/Steve Quake)
- 2011-2013 National Institutes of Health, Program Project Grant
Elafin Therapy of Lung Disease
Co-investigator (Principal Investigator: Marlene Rabinovitch)
- 2010-2012 National Institutes of Health, NHLBI, R34RFA-HL-10-016
Antibody-mediated rejection in lung transplantation
Principal investigator, 2.5% effort
- 2008-2012 APT Pharmaceuticals, Inc., CIS001

The goal of this study is to assess the effectiveness of inhaled cyclosporine in preventing chronic rejection following lung transplantation.
Dr. Weill is the site Principal Investigator
5% effort, \$ 275,351 direct costs/yr

A multi-center, randomized, double-blind, placebo-controlled study to demonstrate the efficacy and safety of cyclosporine inhalation solution (CIS) in improving bronchiolitis obliterans syndrome-free survival following lung transplantation
- 2009-2011 Translational Therapeutics Development Center
Cystic Fibrosis Foundation Therapeutics, Inc MILLA09Y0
Dr. Weill is the Co-Principal Investigator
(Principal Investigator: Carlos Milla)

The major goal of this project is to establish infrastructure support for a clinical trials network related to cystic fibrosis.

- 2008-2011 Program for Adult Care Excellence
Cystic Fibrosis Foundation, WEILL08ACO
Dr. Weill is the Principal Investigator
- The major goal of this project is to enhance the training of adult physicians in the care of adult patients with cystic fibrosis.
- 2007-2011 National Institutes of Health
A Multi center Prospective Cohort Study Examining the Role of Protein C in Early ARDS
Co-investigator (Principal Investigator: Ann Weinacker)
- Goal: Participate in a multicenter trial examining primary graft injury after lung transplantation
Responsibilities: Coordinate patient selection and monitoring with the PI
- 2010-2011 Cystic Fibrosis Center Grant
Cystic Fibrosis Foundation C011-09
Dr. Weill is the Co-Principal Investigator (Principal Investigator: Carlos Milla)
- The major goal of this project is to provide infrastructure support to the Stanford Cystic Fibrosis Center.

Appointments:

Professional:

- 07/96-11/99 Medical Director, Lung and Heart – Lung Transplant Program
Medical City Hospital
Dallas, TX

Academic:

- 01/2021-present Professor of Medicine
Tulane University Medical School
- 04/2017-06/2019 Professor of Medicine and Surgery
Morsani College of Medicine
University of South Florida Health
- 08/01/11-07/01/16 Professor of Medicine
Stanford University School of Medicine
- 05/01/06-07/31/11 Associate Professor of Medicine
Medical Director, Lung and Heart – Lung Transplant Program
Stanford University School of Medicine
- 12/31/05-04/30/06 Acting Associate Professor
Stanford University School of Medicine
- 06/02-11/05 Associate Professor of Medicine
Associate Director, Lung and Heart – Lung Transplant Program

12/99-05/02 University of Colorado Health Sciences Center
Associate Professor of Medicine
Medical Director, Lung and Heart – Lung Transplant Program
University of Alabama – Birmingham

Other Appointments:

06/17-06/19 Executive Advisor, Tampa Transplant Institute at Tampa General Hospital
Tampa General Hospital/University of South Florida Health
12/05-10/15 Director, Center for Advanced Lung Diseases
Medical Director, Lung and Heart-Lung Transplant Program, Stanford
University Medical Center
09/08-07/13 Director, Adult Cystic Fibrosis Program, Stanford University School of
Medicine

Editorial Board Memberships:

1999-2009 Associate Editor, The Journal of Heart and Lung Transplantation
2018-2019 Editor, Pulse Newsletter, International Society of Heart and Lung
Transplantation
2017-2018 Managing Guest Editor, Special Issue, The Monticello Workshop on
Elongate Mineral Particles, Toxicology and Applied Pharmacology

Peer Review Activities:

2017- Present Toxicology and Applied Pharmacology
2014- Present American Journal of Respiratory and Critical Care Medicine
2014- Present Journal of Toxicology and Environmental Health
2014- Present Thorax
2014- Present Critical Reviews in Toxicology
2013- Present The New England Journal of Medicine
1996- Present The Journal of Heart and Lung Transplantation
1996- Present American Journal of Transplantation
1996- Present The Journal of Chronic Obstructive Pulmonary Disease
1996- Present Chest
1996- Present Clinical Transplantation

Major Committee and Service Responsibilities (Administration)

Divisional:

2007- 2008 *Search Committee*, Director, Adult Cystic Fibrosis Program, Stanford
2004- 2005 *Finance Committee*, Division of Pulmonary and Critical Care, University
of Colorado Health Sciences Center

Departmental:

2010- 2012 *Strategic Planning Committee*, Department of Medicine, Stanford

SOM:

2008-Present *Quality Council (Co-Chair)*, Transplantation PPEC, Stanford
 2013-2015 *Search Committee Chair*, Surgical Director, Lung Transplantation,
 Cardiothoracic Surgery, Stanford
 2010-2012 *Faculty Fellow*, Stanford
 2008-2011 *Quality Council*, Cardiothoracic Surgery, Stanford

 2006-2007 *Search Committee, Head*, Thoracic Surgery, Cardiothoracic Surgery,
 Stanford
 2007 *Hand Hygiene Physician Task Force*, Stanford
 2006 *Search Committee*, Pediatric Pulmonary Biology Center Faculty Member,
 Stanford
 2002- 2005 *Antimicrobial Subcommittee*, Pharmacy and Therapeutics Committee,
 University of Colorado Health Sciences Center

Leadership Roles:

2009-2015 Director, Center for Advanced Lung Disease, Stanford University Medical
 Center
 2005-2015 Medical Director, Lung and Heart – Lung Transplant Program, Stanford
 University Medical Center
 2008-2013 Director, Adult Cystic Fibrosis Center, Stanford University Medical
 Center

**Professional Society
Leadership Roles:**

2019-2021 Member, Working Group, Recipient Selection Consensus Document,
 ISHLT
 2008-2016 Member, Medical Advisory Board, California Transplant Donor Network
 2014-2016 Past Chair, Pulmonary Transplantation Council, International Society of
 Heart and Lung Transplantation
 2012-2014 Chair, Pulmonary Transplantation Council, International Society of Heart
 and Lung Transplantation
 2014-2015 Section Editor, ISHLT's reference guide for the work-up and diagnosis of
 common syndromes in thoracic organ transplant recipients
 2009-2011 Vice-Chair, Pulmonary Transplantation Council, International Society of
 Heart and Lung Transplantation
 2008-2011 Pulmonary Council Leader, Standard and Guidelines Committee,
 International Society of Heart and Lung Transplantation

**Meeting Session
Chairman**

Novel Mechanisms in Chronic Lung Allograft Dysfunction, International Society of Heart and Lung Transplantation, April 7, 2017
 Advances in Immunosuppression, International Society of Heart and Lung Transplantation, San Diego, April 14, 2014
 ISHLT Academy: Core Competencies in Lung Transplantation, International Society of Heart and Lung Transplantation, San Diego, April 13, 2011
 The Lung Allocation System, International Society of Heart and Lung Transplantation, Paris, April 23, 2009
 Advances in Immunosuppression, International Society of Heart and Lung Transplantation, San Francisco, April 27, 2009
 Controversies in Cardiothoracic Transplantation, Cardiothoracic Transplantation: An International Update, Vail, CO, February 22, 2003
 Clinical Lung Transplantation, International Society for Heart and Lung Transplantation, Osaka, Japan, April 6, 2000

Committee:

2017 Committee Member, Identifying Collaborative Clinical Research Priorities in Lung Transplantation, National Heart, Lung, and Blood Institute/AATS
 2007- Present Abstract Reviewer, International Meeting, International Society of Heart and Lung Transplantation
 2014-2016 Member, Thoracic Committee, United Network for Organ Sharing
 2008- 2010 Member, Communications Committee, International Society of Heart and Lung Transplantation
 2006-2008 Member, Membership and Professional Standards Committee, United Network for Organ Sharing
 2005-2006 Member, National Lung Review Board, United Network for Organ Sharing
 2003 Member, Working Group on Primary Lung Graft Failure, International Society of Heart and Lung Transplantation
 2001 Member, Maximizing Cadaveric Organ Utilization, American Society of Transplantation

Teaching Record:

Curriculum Development:

Lung Transplant Fellowship
 Stanford University Medical Center
 2005-2015

Lung Transplant Fellowship
 University of Colorado Health Sciences Center
 2002-2005

Lung Transplant Fellowship
University of Alabama – Birmingham
1999-2002

Governmental Consulting:

United States Senate
Environment and Public Works
The Health Effects of Asbestos
June 2007

United States Senate
Judiciary Committee Testimony
Asbestos and Mixed Dust Disease
February 2005

Texas State Legislature Testimony
House Bill 8 Regarding Asbestos and Silica
March 2005

Scientific Consulting:

Chair, Scientific Advisory Board
National Stone, Sand, and Gravel Association
2012-present

Member, Scientific Advisory Board
GlycosBio
2018-present

Member, Scientific Advisory Board
Kallaco
2020-present

Advisory Councils:

Member, The Center for Entrepreneurship
Wake Forest University
2020-present

Publications:**Peer-Reviewed Articles**

1. Cochrane AB, Lyster H, Lindenfeld J, Doligalski C, Baran D, Yost C, Shullo M, Schweiger M, **Weill D**, Stuckey L, Ivulich S, Scheel J, Peters L, Colvin M, Dawson K, Girgis R, Weeks P, Tse T, Russell S, Flattery M, Jennings D, Kittleson M, Miller T, Khuu T, Claridge T, Uber P, Ford K, Ensor CR, Simpson K, Dipchand A, Page RL 2nd. Report from the 2018 consensus conference on immunomodulating agents in thoracic transplantation: Access, formulations, generics, therapeutic drug monitoring, and special populations *J Heart Lung Transplant*. 2020 Oct;39(10):1050-1069.
2. Sethi, JS, Bugajski A, Patel KN, Davis NM, Wille KM, Qureshi MR, Banday MM, Lin M, Emani V, Weill D, Tumin D, Hayes D, Sharma N. Recipient Age Impacts Long-Term Survival in Adult Cystic Fibrosis Subjects after Lung Transplantation. *ANNALSATS* 2020, Aug 14
3. Kheir F, Alkhatib A, Berry GJ, Daroca P, Diethelm L, Rampolla R, Saito S, Smith DL, **Weill D**, Bateman M, Abdelghani R, Lasky JA. Employing Bronchoscopic Lung Cryobiopsy and a Genomic Classifier in the Multidisciplinary Diagnosis of Diffuse Interstitial Lung Diseases *Chest*. 2020 May 25:S0012-3692(20)31499-9
4. **Weill D**. Proceedings of the Monticello Conference on Elongate Mineral Particles. *Toxicol Appl Pharmacol* 2018 Dec 15;361:1-2
5. National Heart, Lung, and Blood Institute and American Association of Thoracic Surgery Workshop: Identifying Collaborative Clinical Research Priorities in lung transplantation. Mulligan MS, **Weill D**, Davis RD, Christie JD, Farjah F, Singer JP, Hartwig M, Sanchez PG, Kreisel D, Ware LB, Bermudez C, Hachem RR, Weyant MJ, Gries C, Awori Hayanga JW, Griffith BP, Snyder LD, Odum J, Craig JM, Aggarwal NR, Reineck LA. *J Thorac Cardiovasc Surg* 2018 Aug 18. pii: S0022-5223(18)32135-4
6. **Weill D**. Lung transplantation: indications and contraindications. *J Thorac Dis* 2018;10(7):4574-4587
7. Hachem RR, Kamoun M, Budev MM, Askar M, Ahya VN, Lee JC, Levine DJ, Pollack MS, Dhillon GS, **Weill D**, Schechtman KB, Leard LE, Golden JA, Baxter-Lowe L, Mohanakumar T, Tyan DB, Yusen RD. Human leukocyte antibodies after lung transplantation: Primary Results of the HALT Study. *Am J Transplant*. 2018 Apr 24
8. Snell GI, Yusen RD, **Weill D**, Strueber M, Garrity E, Reed A, Pelaez A, Whelan TP, Perch M, Bag R, Budev M, Corris PA, Crespo MM, Witt C, Cantu E, Christie JD. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction, part I: Definition and Grading – A 2016 Consensus group statement of the International Society for the Heart and Lung Transplantation *J Heart Lung Transplant*. 2017 Oct;36(10):1097-1103
9. Cantu E, Diamond JM, Suzuki Y, Lasky J, Schaufler C, Lim B, Shah R, Porteous M, Lederer DJ, Kawut SM, Palmer SM, Snyder LD, Hartwig MG, Lama VN, Bhorade S, Bermudez C, Crespo M, McDyer J, Wille K, Orens J, Shah PD, Weinacker A, **Weill D**, Wilkes D, Roe D, Hage C, Ware LB, Bellamy SL, Christie JD; Lung Transplant Outcomes Group. *Am J Respir Crit Care Med*. 2017 Sep 5
10. Pasupneti S, Patel K, Mooney JJ, Chhatwani L, Dhillon G, **Weill D**. Lung transplantation following death by drowning: a review of the current literature. *Clin Transplant*. 2016 Oct

11. Mooney JJ, **Weill D**, Boyd JH, Nicolls MR, Bhattacharya J, Dhillon GS. Effect of Transplant Center Volume on Cost and Readmissions in Medicare Lung Transplant Recipients. *Ann Am Thorac Soc*. 2016 Apr 11
12. Yang RL, Kurian AW, Winton LM, **Weill D**, Patel K, Kingham K, Wapnir IL. Addressing inherited predisposition for breast cancer in transplant recipients. *J Surg Oncol*. 2016 Feb
13. Yang RL, Kurian AW, Winton LM, **Weill D**, Patel K, Kingham K, Wapnir IL. Addressing inherited predisposition for breast cancer in transplant recipients. *J Surg Oncol*. 2016 Feb.
14. Cantu E, Suzuki Y, Diamond JM, Ellis J, Tiwari J, Beduhn B, Nellen JR, Shah R, Meyer NJ, Lederer DJ, Kawut SM, Palmer SM, Snyder LD, Hartwig MG, Lama VN, Borhade S, Crespo M, Demissie E, Wille K, Orens J, Shah PD, Weinacker A, **Weill D**, Wilkes D, Roe D, Ware LB, Wang F, Feng R, Christie JD. Lung Transplant Outcomes Group. Protein Quantitative Trait Loci Analysis Identifies Genetic Variation in the Innate Immune Regulator TOLLIP in Post-Lung Transplant Primary Graft Dysfunction Risk. *Am J Transplant*. 2015 Dec.
15. Hill C, Maxwell B, Boulate D, Haddad F, Ha R, Afshar K, **Weill D**, Dhillon GS. Heart-lung vs. double-lung transplantation for idiopathic pulmonary arterial hypertension. *Clin Transplant*. 2015 Dec;29(12):1067-75.
16. Iwijn De Vlaminck, Lance Martina, Michael Kertesza, Kapil Patel, Mark Kowarsky, Calvin Strehle, Garrett Cohene, Helen Luikart, Norma F. Neff, Jennifer Okamoto, Mark R. Nicolls, David Cornfield, **Weill D**, Hannah Valentine, Kiran K. Khush, and Stephen R. Quake. Noninvasive monitoring of infection and rejection after lung transplantation. *PNAS*. 2015 Oct;112(43):13336-41.
17. **Weill D**, Benden C, Corris PA, Dark JH, Davis RD, Keshavjee S, Lederer DJ, Mulligan MJ, Patterson GA, Singer LG, Snell GI, Verleden GM, Zamora MR, Glanville AR. A consensus document for the selection of lung transplant candidates: 2014 – an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. *J Heart Lung Transplant*. 2015 Jan;34(1):1-15.
18. Maxwell BG, Mooney JJ, Lee PH, Levitt JE, Chhatwani L, Nicolls MR, Zamora MR, Valentine V, **Weill D**, Dhillon GS. Increased resource utilization in lung transplant admissions in the Lung Allocation Score era. *Am J Respir Crit Care Med*. 2014 Dec 17.
19. Maxwell BG, Levitt JE, Goldstein BA, Mooney JJ, Nicolls MR, Zamora M, Valentine V, **Weill D**, Dhillon GS. Impact of the lung allocation score on survival beyond 1 year. *Am J Transplant*. 2014 Oct;14(10):2288-94.
20. De Vlaminck I, Khush KK, Strehl C, Kohli B, Luikart H, Neff NF, Okamoto J, Snyder TM, Cornfield DN, Nicolls MR, **Weill D**, Bernstein D, Valentine HA, Quake SR. Temporal response of the human virome to immunosuppression and antiviral therapy. *Cell* 2013 Nov 21;155(5):1178-87.
21. Diamond JM, Porteous MK, Cantu E, Meyer NJ, Shah RJ, Lederer DJ, Kawut SM, Lee J, Bellamy SL, Palmer SM, Lama VN, Borhade SM, Crespo M, Demissie E, Wille K, Orens J, Shah PD, Weinacker A, **Weill D**, Arcasoy S, Wilkes DS, Ware LB, Christie JD; Lung Transplant Outcomes Group. Elevated plasma angiotensin-2 levels and primary graft dysfunction after lung transplantation. *PLoS One* 2012;7(12):e51932.
22. Diamond JM, Meyer NJ, Feng R, Rushefski M, Lederer DJ, Kawut SM, Lee JC, Cantu E, Shah RJ, Lama VN, Borhade S, Crespo M, Demissie E, Sonett J, Wille K, Orens J, Weinacker A, **Weill D**, Arcasoy S, Shah PD, Belperio JA, Wilkes D, Ware LB, Palmer

- SM, Christie JD. Variation in PTX3 is associated with primary graft dysfunction after lung transplantation. *Am J Respi Crit Care Med* 2012 Sep 15;186(6):546-52.
23. Dhillon G, Valentine V, Levitt J, Gupta M, Duncan S, Seoane L, and **Weill D**. Clarithromycin for prevention of bronchiolitis obliterans syndrome in lung allograft recipients. *Clinical Transplantation*. 2012 Jan-Feb;26(1):105-10.
24. Diamond JM, Lederer DJ, Kawut SM, Lee J, Ahya VN, Bellamy S, Palmer SM, Lama VN, Bhorade S, Crespo M, Demissie E, Sonnett J, Wille K, Orens J, Sha PD, Weinacker A, **Weill D**, Kohl BA, Deutschman CC, Arcasoy S, Shah AS, Belpierio JA, Wilkes D, Reynolds JM, Ware LB, Christie JD. Elevated plasma long pentraxin-3 levels and primary graft dysfunction after lung transplantation for idiopathic pulmonary fibrosis. *Am J Transplant* 2011 Nov;11(11):2517-22.
25. Liu V, **Weill D**, Bhattacharya J. Racial Disparities in Survival After Lung Transplantation. *Arch Surg* 2011 Mar;146(3):286-93.
26. Liu V, Bhattacharya J, **Weill D**, Hunt S, and Hlatky MA. Persistent racial disparities in survival following heart transplantation. *Circulation* 2011 Apr 19;123(15):1642-9. *My primary role in this study was to provide significant editing to the manuscript. I also took the primary responsibility for answering the reviewers' questions.*
27. **Weill D**, Dhillon G, Freyder L, Lefante J, and Glindmeyer H. Lung function, radiologic changes, and exposure: analysis of ATSDR data from Libby, Montana. *European Respiratory Journal* 2011 Aug;38(2):376-83.
28. Dhillon GS, Zamora MR, Roos JE, Sheahan D, Sista RR, van der Starre P, **Weill D**, Nicolls MR. Lung transplant airway hypoxia: a diathesis to fibrosis. *Am J Respir Crit Care Med*. 2010 Jul 15;182(2):230-6. *My primary role in this study was to provide significant editing to the manuscript. I also took the primary responsibility for answering the reviewers' questions.*
29. Deuse T, Sista R, **Weill D**, Haddad F, Dhillon G, Robbins RC, and Reitz BA. Review of heart-lung transplantation at Stanford. *Ann Thorac Surg* 2010 Jul; 90(1):329-37. *My primary role in this study was to provide significant editing to the manuscript. I also took the primary responsibility for answering the reviewers' questions.*
30. Chang W, Wei K, Jacobs SS, Upadhyay D, **Weill D**, and Rosen GD. SPARC suppresses apoptosis of idiopathic pulmonary fibrosis fibroblasts through constitutive activation of beta-catenin. *J Biol Chem*. 2010 Mar 12;285(11):8196-206. *My role in this study was to take the primary role in collecting the clinical data for analysis. My secondary role was to heavily edit the manuscript.*
31. Liu V, Zamora MR, Dhillon GS, and **Weill D**. Increasing Lung Allocation Scores Predict Worsened Survival among Lung Transplant Recipients. *American Journal of Transplantation* 2010 Apr;10(4):915-20.
32. Liu V, Dhillon GS, and **Weill D**. A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients. *Transpl Infect Dis* 2010 Feb;12(1):38-44.
33. Choi JY, Khansaheb M, Joo NS, Krouse ME, Robbins RC, **Weill D**, and Wine JJ. Substance P stimulates airway submucosal gland secretion mainly via a CFTR – dependent process. *Journal of Clinical Investigation* 2009 May;119(5):1189-200. *My role in this study was to take the primary role in collecting the clinical data for analysis. My secondary role was to heavily edit the manuscript.*
34. Valentine VG, **Weill D**, Lombard GA, LaPlace SG, Seoane L, Taylor DE, Dhillon GS. A Single Institution Study Evaluating the Utility of Surveillance Bronchoscopy Following Lung Transplantation. *Journal of Heart and Lung Transplantation* 2009

- Jan;28(1):14-20. *My primary role in this study was to provide significant editing to the manuscript. I also took the primary responsibility for answering the reviewers' questions.*
35. Dhillon GS, Levitt J, Mallidi H, Valentine VG, Gupta MR, Sista R, and **Weill D**. Impact of Hepatitis B core antibody positive donors in lung and heart-lung transplantation: an analysis of the United Network for Organ Sharing database. *Transplantation* 2009; 88:842-846.
 36. Valentine VG, **Weill D**, Raper B, Lombard GA, LaPlace SG, Bonvillain RW, Seoane L, Taylor DE, Dhillon GS. Ganciclovir for Cytomegalovirus: A Call for Indefinite Prophylaxis in Lung Transplantation. *Journal of Heart and Lung Transplantation* 2008 Aug;27(8):875-81. *My primary role in this study was to provide significant editing to the manuscript. I also took the primary responsibility for answering the reviewers' questions.*
 37. Leung M, Rachakonda L, **Weill D**, and Hwang P. Outcomes of Sinus Surgery before Lung Transplantation for Cystic Fibrosis. *American Journal of Rhinology* 2008 Mar – Apr; 22(2): 192 – 6. *My role in this study was to take the primary role in collecting the clinical data for analysis. My secondary role was to heavily edit the manuscript.*
 38. Mulligan MS, Shearon TH, **Weill D**, Pagani FD, Moore J, and Murray S. Heart and Lung Transplantation in the United States, 1997-2006. *American Journal of Transplantation* 2008 Apr; 8(4 Pt 2):977-87. *My primary role in this study was to provide significant editing to the manuscript. I also took the primary responsibility for answering the reviewers' questions.*
 39. Astor TL, **Weill D**, Cool C, Teitlebaum I, Schwarz MI and Zamora MR. Pulmonary capillaritis in lung transplant recipients: treatment and effect on allograft function. *Journal of Heart and Lung Transplantation* 2005; 24:2091-7. *My primary role in this study was to provide significant editing to the manuscript. I also took the primary responsibility for answering the reviewers' questions.*
 40. Christie JD, Carby M, Bag R, Corris P, Hertz M, and **Weill D**. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction Part II: Definition. A Consensus Statement of the International Society for Heart and Lung Transplantation. *Journal of Heart and Lung Transplantation* 2005 Oct; 24(10):1454-9.
 41. Zamora MR, Nicolls MR, Hodges TN, Marquesen J, Astor TL, Grazia T, and **Weill D**. Following Universal Prophylaxis with Intravenous Ganciclovir and Cytomegalovirus Immune Globulin, Valganciclovir is Safe and Effective for Prevention of CMV Infection Following Lung Transplantation. *American Journal of Transplantation* 2004 Oct; 4(10):1635-42.
 42. Dransfield MT, Garver RI, and **Weill D**. Standardized guidelines for surveillance bronchoscopy reduce complications in lung transplant recipients. *Journal of Heart and Lung Transplantation* 2004; 23(1):110-4.
 43. Zorn GL, McGiffin DC, Young KR, Alexander CB, **Weill D**, and Kirklin JK. Pulmonary transplantation for advanced bronchioloalveolar carcinoma. *Journal of Thoracic and Cardiovascular Surgery* 2003; 125(1):45-8. *My role in this study was to take the primary role in collecting the clinical data for analysis. My secondary role was to heavily edit the manuscript.*
 44. **Weill D**, Lock BJ, Wewers DL, Young KR, Zorn GL, Early L, Kirklin JK, and McGiffin DC. Combination prophylaxis with ganciclovir and cytomegalovirus immune globulin after lung transplantation: Effective CMV prevention following daclizumab induction. *American Journal of Transplantation* 2003; 3(4):492-496.

45. **Weill D**, Dey GC, Hicks RA, Young KR, Zorn GL, Kirklin JK, Early L, and McGiffin DC. A positive donor gram stain does not predict outcome following lung transplantation. *Journal of Heart and Lung Transplantation* 2002; 21(5):555-8.
46. Schmidt F, McGiffin DC, Zorn G, Young KY, **Weill D**, and Kirklin JK. Management of congenital abnormalities of the donor lung. *Annals of Thoracic Surgery* 2001; 72(3):935-7. *My role in this study was to take the primary role in collecting the clinical data for analysis. My secondary role was to heavily edit the manuscript.*
47. Nemunaitis J, Swisher SG, Mack M, **Weill D**, Merritt J, and Roth J. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small cell lung cancer. *Journal of Clinical Oncology* 2000; 18(3):609-622. *My role in this study was to take the primary role in collecting the clinical data for analysis. My secondary role was to heavily edit the manuscript.*
48. **Weill D**, Mack MJ, Roth J, Swisher S, Proksch, Merritt J, and Nemunaitis J. Adenoviral-mediated p53 gene transfer to non-small cell lung cancer through endobronchial injection. *Chest* 2000; 118:966-70.
49. **Weill D**, McGiffin DC, Zorn GL, Alexander CB, Early LJ, Kirklin JK, and Young KR. The utility of open lung biopsy following lung transplantation. *Journal of Heart and Lung Transplantation* 2000; 19(9):852-857.
50. Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, Carrasco CH, Connors DG, El-Naggar AK, Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Mack M, Merritt JA, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KM, Putnam JB, Richli WR, Savin M, Schrupp DS, Shin DM, Shulkin A, Walsh GL, Wait J, **Weill D**, and Waugh MK. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. *J Natl Cancer Inst.* 1999 May 5; 91(9):763-71. *My role in this study was to take the primary role in collecting the clinical data for analysis. My secondary role was to heavily edit the manuscript.*
51. **Weill D**, Hodges TN, Torres F, and Zamora MR. Acute native lung hyperinflation is not associated with a poor outcome following single lung transplantation for emphysema. *Journal of Heart and Lung Transplantation* 1999; 18:1080-1087.
52. Badesch DB, Zamora MR, **Weill D**, and Schwarz MI. Pulmonary capillaritis: a possible histologic form of acute allograft rejection. *Journal of Heart and Lung Transplantation* 1998; 17(4):415-422. *My role in this study was to take the primary role in collecting the clinical data for analysis. My secondary role was to heavily edit the manuscript.*
53. Terada LS, Hybertson BM, **Weill D**, and Repine JE. XO increases neutrophil adherence to endothelial cells by a dual mechanism. *Journal of Applied Physiology* 1997; 82(3):866-873. *My role in this study was to provide technical support in the experimental model for the more senior researchers. My secondary role was to write the sections regarding the scientific methodology.*
54. Beaver TM, Fullerton DA, **Weill D**, and Grover FL. Colon perforation after lung transplantation. *Annals of Thoracic Surgery* 1996; 62:839-843. *My role in this study was to take the primary role in collecting the clinical data for analysis. My secondary role was to heavily edit the manuscript.*

Editorials

1. **Weill D**. Access to Lung Transplantation: The Long and Short of It. *Am J Respir Crit Care Med.* 2016 Mar 15;193(6):605-6.
2. **Weill D**. Twenty years of lung transplantation: areas of improvements and challenges. *Minerva Pneumologica* 2003; 42:139-57.

3. **Weill D.** Donor criteria in lung transplantation: an issue revisited. *Chest* 2002; 121:2029-2031.
4. **Weill D** and Keshavjee S. Lung Transplantation for Emphysema: Two Lungs or One? *Journal of Heart and Lung Transplantation* 2001; 20(7):739-742.
5. **Weill D.** Role of cytomegalovirus in cardiac allograft vasculopathy. *Transplant Infectious Disease* 2001 Suppl 2:3:44-48.

Reviews

1. Galbraith D and **Weill D.** Popcorn Lung and Bronchiolitis Obliterans: A Critical Appraisal. *International Archives and Environmental Health* 2008 June 12.
2. Astor TL and **Weill D.** Extracorporeal photopheresis in lung transplantation. *Journal of Cutaneous Medicine and Surgery* 2003 Sep 9.
3. **Weill D,** Mack MJ, and Tennison D. Adverse effects of medications commonly administered to thoracic surgical patients. *Chest Surgery Clinics of North America, Medical Complications of Thoracic Surgery*, August 1999.

Book Chapters/Monographs

1. **Weill D.** The history of lung transplantation. *The Psychosocial Care of the End-Stage Disease and Transplant Patients*. Editors: Sher and Maldonado, 2018.
2. **Weill D.** Lung transplantation: indications and contraindications. *Lung Transplantation in the Third Millennium*. Editors: Van Raemdonck and Venuta, 2018.
3. Dhillon GS and **Weill D.** Recipient management before transplantation. *Lung Transplantation: Principles and Practice*. Editors: Vigneswaran and Garrity, 2016.
4. **Weill D.** Asbestos and asbestos-related diseases. *Hunter's Diseases of Occupation*, 10th Edition, Editors: Baxter, Aw, Cockcroft, Durrington, and Harrington, 2010.
5. **Weill D.** The Clinical Aspects of the Asbestos Associated Diseases. *Asbestos and Its Diseases*, 1st Edition, Editors: Craighead and Gibbs, 2008.
6. Astor TL and **Weill D.** Oxidative Lung Injury. *Textbook of Critical Care*, 5th Edition, Editors: Fink, Abraham, Vincent, Kochanek, 2005.
7. **Weill D.** Lung Transplantation. *Textbook of Critical Care*, 5th Edition, Editors: Fink, Abraham, Vincent, Kochanek, 2005.
8. **Weill D,** Rose C, and King TE. Treatment and prognosis of hypersensitivity pneumonitis. *UPTODATE in Pulmonary and Critical Care Medicine*, 1997, American Thoracic Society.
9. **Weill D** and Zamora MR. Postoperative care in lung transplantation. *Seminars in Respiratory Medicine* 1996; 17(2):159-165.
10. **Weill D** and Make B. Oxygen Conserving Devices. *Long-Term Oxygen Therapy*, New York: Marcel Dekker, 1994; 234-256.

Letters

1. **Weill D,** Chatfield E, Cox A Jr, Gamble J, Gibbs G, Wylie A. In reference to Hwang et al. "The Relationship Between Various Exposure Metrics for Elongate Mineral Particles (EMP) in the Taconite Mining and Processing Industry" *J Occup Envir Hyg*. 2015 Jan 23.
2. Galbraith DA and **Weill D.** Authors' response to Kreiss et al. *Int Arch Occup Environ Health* 2010 Feb;83(2):237-40.

3. Finley BL, Galbraith DA, and **Weill D**. Comments on respiratory toxicity of diacetyl. *Toxicol Sci* 2008 Oct;105(2):429-32.
4. Galbraith DA and **Weill D**. Diacetyl and bronchiolitis obliterans. *Am J Respir Crit Care Med* 2008 Aug 1;178(3):313.
5. **Weill D** and Weill H. Diagnosis and initial management of nonmalignant diseases related to asbestos. *Am J Respir Crit Care Med*. 2005 Mar 1; 171(5):527-528.
6. **Weill D** and Zamora MR. Comparison of the efficacy and cost effectiveness of preemptive therapy as directed by CMV antigenemia and prophylaxis with ganciclovir in lung transplant recipients. *Journal of Heart and Lung Transplantation* 2000; 19(8):815-6.

Oral Presentations (competitive)

1. Dhillon GS, Zamora MR, Roos JE, Sheahan D, Sista RR, Van der Starre P, **Weill D**, Nicolls MR. Lung Transplant Airway Hypoxia: A Diathesis to Fibrosis? American Thoracic Society Annual Meeting, New Orleans, May 2010.
2. **Weill D**, Young R, and McGiffin DC. A Positive Donor Gram Stain Does Not Predict the Development of Pneumonia, Oxygenation, or Duration of Mechanical Ventilation Following Lung Transplantation, International Society of Heart and Lung Transplantation, April, 2001.
3. **Weill D**, Young R, And McGiffin DC. The Utility of Open Lung Biopsy Following Lung Transplantation, 4th International Congress on Lung Transplantation, September, 2000.
4. **Weill D**, Magee M, Dewey T, and Mack MJ. Impact of Donor Gram Stain on Recipient Outcome Following Lung Transplantation, International Society of Heart and Lung Transplantation, April, 2000.
5. **Weill D**, Torres, F, Hodges TN, and Zamora MR. Acute Native Lung Hyperinflation Following Single Lung Transplantation for Emphysema, International Society of Heart and Lung Transplantation, April, 1999.
6. **Weill D**. p53 Oncogene Transfers to Non-Small Cell Lung Cancers, American Association of Thoracic Surgeons, May, 1998.

Invited Extramural Lectures and Presentations

April 2016	The Preoperative Selection of Lung Transplant Candidates with Malignancy, ISHLT, Washington D.C.
February 2016	The Lung Allocation Score: Morbidity, Mortality, and Resource Utilization, The Methodist Hospital, Houston, Texas
April 2014	The Report on Recipient Selection Consensus Document, ISHLT, San Diego, CA
May 2008	Lung Transplantation: Where We Have Been and Where We Are Going, Stanford University, Medical Grand Rounds
March 2008	Expanding the Donor Pool, Plenary Session, Transplant Growth and Collaborative Meeting, Department of Health and Human Services
December 2006	Cytomegalovirus Infections Following Lung Transplantation, Stanford University, Medical Grand Rounds
February 2006	Lung Transplantation 2006, University of California – Davis, Pulmonary Grand Rounds
December 2004	An Update on Lung Transplantation, University of West Virginia Medical School,

September 2004	Pulmonary Grand Rounds Current Aspects of Lung Transplantation, University of Texas-Southwestern, Pulmonary Grand Rounds
June 2003	Post Transplant Thoracic Malignancies, Texas Transplant Society Annual Meeting
June 2003	An Update on Bronchiolitis Obliterans Syndrome, University of Southern California Medical School, Pulmonary Grand Rounds
March 2003	Expanding the Donor Pool, International Meeting, American Society of Transplant Physicians and Surgeons
February 2003	Lung Transplantation for COPD: Two Lungs, One, or None, Cardiothoracic Transplantation: An International Update, Vail, CO
November 2002	Photopheresis in Lung Transplantation, Johns Hopkins Medical School
October 2002	Lung Transplantation: An Update, University of Colorado Health Sciences Center, Medical Grand Rounds
February 2002	Expanding the Donor Pool, Oregon Health Sciences Center Transplant Grand Rounds
February 2002	Cytomegalovirus Infections in Thoracic Transplantation, University of Texas – San Antonio Transplant Grand Rounds
December 2001	An Update on Immunosuppression, Indiana University/Methodist Hospital Transplant Grand Rounds
February 2001	Lung Transplantation for Bronchioloalveolar Carcinoma, Cardiothoracic Transplantation 2001: An International Update
July 2000	Current Aspects of Lung Transplantation. Medical Grand Rounds, University of Alabama- Birmingham
September 2000	Late Complications Following Lung Transplantation, Lung Transplantation 2000, Mount Sinai Medical Center
June 1997	Tolerance to Acute Lung Injury, Louisiana State University Pulmonary Grand Rounds

Board of Directors

2021-present	Xavier University of Louisiana New Orleans, Louisiana
2019-present	TransMedics Boston, Massachusetts
2019-present	Tulane University Medical School New Orleans, Louisiana
2018-present	Elevate USA New Orleans, Louisiana
2018-present	KatyCares New Orleans, Louisiana
2016-present	Next Gen Personal Finance Palo Alto, California
2015-present	Rosemary Beach Property Owners Association Rosemary Beach, Florida

2014-present Isidore Newman School
New Orleans, Louisiana